[go: up one dir, main page]

MX2020014003A - Proteinas inmunodominantes y fragmentos en esclerosis multiple. - Google Patents

Proteinas inmunodominantes y fragmentos en esclerosis multiple.

Info

Publication number
MX2020014003A
MX2020014003A MX2020014003A MX2020014003A MX2020014003A MX 2020014003 A MX2020014003 A MX 2020014003A MX 2020014003 A MX2020014003 A MX 2020014003A MX 2020014003 A MX2020014003 A MX 2020014003A MX 2020014003 A MX2020014003 A MX 2020014003A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
fragments
immunodominant proteins
immunodominant
proteins
Prior art date
Application number
MX2020014003A
Other languages
English (en)
Inventor
Roland Martin
Ramos Mireia Sospedra
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of MX2020014003A publication Critical patent/MX2020014003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

La descripción se refiere al tratamiento, diagnóstico y/o prevención de esclerosis múltiple (MS) al utilizar una proteína o péptido inmunodominante. De manera más particular la invención se refiere al campo de inmunoterapias específicas de antígeno, tal como la inducción de tolerancia.
MX2020014003A 2018-06-28 2019-06-28 Proteinas inmunodominantes y fragmentos en esclerosis multiple. MX2020014003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180326.3A EP3586866A1 (en) 2018-06-28 2018-06-28 Immunodominant proteins and fragments in multiple sclerosis
PCT/EP2019/067468 WO2020002674A1 (en) 2018-06-28 2019-06-28 Immunodominant proteins and fragments in multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2020014003A true MX2020014003A (es) 2021-03-25

Family

ID=62814962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014003A MX2020014003A (es) 2018-06-28 2019-06-28 Proteinas inmunodominantes y fragmentos en esclerosis multiple.

Country Status (21)

Country Link
US (2) US12527846B2 (es)
EP (3) EP3586866A1 (es)
JP (2) JP2021528965A (es)
KR (1) KR20210041559A (es)
CN (2) CN112512554A (es)
AU (1) AU2019294465A1 (es)
BR (1) BR112020026458A2 (es)
CA (1) CA3104231A1 (es)
CL (1) CL2020003355A1 (es)
CO (1) CO2020016105A2 (es)
CR (1) CR20200642A (es)
EC (1) ECSP20083339A (es)
ES (1) ES3042684T3 (es)
IL (1) IL279608A (es)
JO (1) JOP20200329A1 (es)
MX (1) MX2020014003A (es)
PE (1) PE20211739A1 (es)
PH (1) PH12020552222A1 (es)
SG (1) SG11202012661WA (es)
WO (1) WO2020002674A1 (es)
ZA (1) ZA202007822B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112710843B (zh) * 2020-12-16 2022-11-04 江苏伟禾生物科技有限公司 一种测定群体反应性抗体检测的板式免疫荧光试剂盒及其制备方法
US20240329043A1 (en) 2021-07-16 2024-10-03 Universität Zurich Method for stratification and treatment of multiple sclerosis
EP4119948A1 (en) 2021-07-16 2023-01-18 Universität Zürich Method for stratification and treatment of multiple sclerosis
WO2024094562A1 (en) 2022-11-01 2024-05-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis
EP4553083A1 (en) * 2023-11-10 2025-05-14 Cellerys AG Peptides and their use for the treatment and/or prevention of multiple sclerosis
AR134272A1 (es) * 2023-11-10 2025-12-17 Univ Zuerich Peptidos y su uso para el tratamiento y/o la prevencion de esclerosis multiple

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5932443A (en) * 1997-09-26 1999-08-03 Incyte Pharmaceuticals, Inc. Human antigens
JP2001145488A (ja) * 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のｇｄｐ−４−ケト−６−デオキシ−ｄ−マンノース−３，５−エピメラーゼ−４−レダクターゼ遺伝子
US6743904B2 (en) 2001-03-14 2004-06-01 Applera Corporation Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
JP2005500038A (ja) 2001-06-22 2005-01-06 ヤンゼン、ブルクハルト 多発性硬化症のヒトの診断方法
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
WO2004050900A2 (en) 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
JP2006141297A (ja) * 2004-11-19 2006-06-08 Eiken Chem Co Ltd 血管新生を検出するためのマーカー
WO2007013359A2 (en) * 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Cancer related gene rasgef1a
EP1960792A2 (en) 2005-12-07 2008-08-27 Boehringer Ingelheim International Gmbh Treatment and diagnostics of inflammatory diseases
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
WO2009062260A1 (en) 2007-11-15 2009-05-22 David Richmond Booth Therapy for multiple sclerosis
CA2724475C (en) 2008-05-16 2019-05-07 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes
PL2318020T3 (pl) 2008-06-30 2016-02-29 Univ Heidelberg Immunosupresyjne komórki krwi i sposób ich wytwarzania
EP2437060A1 (de) * 2010-10-01 2012-04-04 Protagen AG Markersequenzen für Multiple Sklerose und deren Verwendung
DE102010042359A1 (de) * 2010-10-12 2012-04-12 Protagen Ag Markersequenzen für Multiple Sklerose und deren Verwendung
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
US20160032344A1 (en) 2013-03-15 2016-02-04 Glycobia, Inc. Polysialic acid, blood group antigens and glycoprotein expression in prokaryotes
WO2015038963A1 (en) * 2013-09-12 2015-03-19 Teva Pharmaceutical Industries, Ltd. Gene expression biomarkers of laquinimod responsiveness
CN107502615B (zh) * 2017-10-16 2020-05-05 中国海洋大学 海带中编码gdp-甘露糖-4,6-脱水酶的基因、及其蛋白质和用途

Also Published As

Publication number Publication date
EP3813865C0 (en) 2025-08-06
WO2020002674A1 (en) 2020-01-02
CA3104231A1 (en) 2020-01-02
CN119971002A (zh) 2025-05-13
KR20210041559A (ko) 2021-04-15
IL279608A (en) 2021-03-01
EP3813865B1 (en) 2025-08-06
SG11202012661WA (en) 2021-01-28
CN112512554A (zh) 2021-03-16
CO2020016105A2 (es) 2021-03-19
EP3813865A1 (en) 2021-05-05
JOP20200329A1 (ar) 2019-06-28
JP2024116146A (ja) 2024-08-27
CL2020003355A1 (es) 2021-07-23
AU2019294465A1 (en) 2021-01-14
JP2021528965A (ja) 2021-10-28
PH12020552222A1 (en) 2021-06-28
ZA202007822B (en) 2021-10-27
ES3042684T3 (en) 2025-11-24
EP3586866A1 (en) 2020-01-01
EP4640282A2 (en) 2025-10-29
BR112020026458A2 (pt) 2021-05-25
US20250332229A1 (en) 2025-10-30
EP4640282A3 (en) 2025-12-31
ECSP20083339A (es) 2021-03-31
PE20211739A1 (es) 2021-09-06
US12527846B2 (en) 2026-01-20
US20210162019A1 (en) 2021-06-03
CR20200642A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2020003190A (es) Degradadores de proteinas y usos de los mismos.
WO2018187356A3 (en) Protein antigens and uses thereof
MX379450B (es) Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares
MX2025000260A (es) Proteina de union al antigeno anti-steap1
NZ737796A (en) Anti-tau antibodies and methods of use
MX2017004007A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
EA201890355A1 (ru) Новые способы индукции иммунного ответа
WO2018160896A8 (en) Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
TN2017000417A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
GB201206070D0 (en) Clostridium difficile antigens
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
EP4406613A3 (en) Immunogenic arginase peptides
PH12021551422A1 (en) Anti-il-36 antibodies and methods of use thereof
ZA202110285B (en) Antibodies and methods of use
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
WO2021005338A3 (en) Novel cancer antigens and methods
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
WO2020079448A9 (en) Novel cancer antigens and methods
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2018011193A (es) Proteinas derivadas de alfa-1-microglobulina novedosas y su uso.
PH12022550671A1 (en) Antigen binding proteins
WO2020053742A3 (en) Anti-hla-hbv peptide antibodies
WO2019093638A3 (ko) 오리엔티아 쯔쯔가무시 균의 scaa 유래 신규 재조합 단백질 항원 및 이를 이용한 백신 조성물